327 related articles for article (PubMed ID: 27341434)
1. In Vivo Conformational Dynamics of Hsp90 and Its Interactors.
Chavez JD; Schweppe DK; Eng JK; Bruce JE
Cell Chem Biol; 2016 Jun; 23(6):716-26. PubMed ID: 27341434
[TBL] [Abstract][Full Text] [Related]
2. Atomistic simulations and network-based modeling of the Hsp90-Cdc37 chaperone binding with Cdk4 client protein: A mechanism of chaperoning kinase clients by exploiting weak spots of intrinsically dynamic kinase domains.
Czemeres J; Buse K; Verkhivker GM
PLoS One; 2017; 12(12):e0190267. PubMed ID: 29267381
[TBL] [Abstract][Full Text] [Related]
3. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
4. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle.
Li J; Richter K; Reinstein J; Buchner J
Nat Struct Mol Biol; 2013 Mar; 20(3):326-31. PubMed ID: 23396352
[TBL] [Abstract][Full Text] [Related]
5. Stability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2.
Olesen SH; Ingles DJ; Zhu JY; Martin MP; Betzi S; Georg GI; Tash JS; Schönbrunn E
Molecules; 2015 Jan; 20(1):1643-60. PubMed ID: 25608045
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
7. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study.
Verma S; Singh A; Mishra A
J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743
[TBL] [Abstract][Full Text] [Related]
9. The joining of the Hsp90 and Hsp70 chaperone cycles yields transient interactions and stable intermediates: insights from mass spectrometry.
Schmidt C; Beilsten-Edmands V; Robinson CV
Oncotarget; 2015 Jul; 6(21):18276-81. PubMed ID: 26286954
[TBL] [Abstract][Full Text] [Related]
10. Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions.
Walerych D; Olszewski MB; Gutkowska M; Helwak A; Zylicz M; Zylicz A
Oncogene; 2009 Dec; 28(48):4284-94. PubMed ID: 19749793
[TBL] [Abstract][Full Text] [Related]
11. Domain:domain interactions within Hop, the Hsp70/Hsp90 organizing protein, are required for protein stability and structure.
Carrigan PE; Sikkink LA; Smith DF; Ramirez-Alvarado M
Protein Sci; 2006 Mar; 15(3):522-32. PubMed ID: 16452615
[TBL] [Abstract][Full Text] [Related]
12. Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90-Client Interactions.
Paladino A; Woodford MR; Backe SJ; Sager RA; Kancherla P; Daneshvar MA; Chen VZ; Bourboulia D; Ahanin EF; Prodromou C; Bergamaschi G; Strada A; Cretich M; Gori A; Veronesi M; Bandiera T; Vanna R; Bratslavsky G; Serapian SA; Mollapour M; Colombo G
Chemistry; 2020 Aug; 26(43):9459-9465. PubMed ID: 32167602
[TBL] [Abstract][Full Text] [Related]
13. Low sequence identity but high structural and functional conservation: The case of Hsp70/Hsp90 organizing protein (Hop/Sti1) of Leishmania braziliensis.
Batista FAH; Seraphim TV; Santos CA; Gonzaga MR; Barbosa LRS; Ramos CHI; Borges JC
Arch Biochem Biophys; 2016 Jun; 600():12-22. PubMed ID: 27103305
[TBL] [Abstract][Full Text] [Related]
14. Large Rotation of the N-terminal Domain of Hsp90 Is Important for Interaction with Some but Not All Client Proteins.
Daturpalli S; Knieß RA; Lee CT; Mayer MP
J Mol Biol; 2017 May; 429(9):1406-1423. PubMed ID: 28363677
[TBL] [Abstract][Full Text] [Related]
15. From Conformation to Interaction: Techniques to Explore the Hsp70/Hsp90 Network.
Batista FA; Gava LM; Pinheiro GM; Ramos CH; Borges JC
Curr Protein Pept Sci; 2015; 16(8):735-53. PubMed ID: 25961397
[TBL] [Abstract][Full Text] [Related]
16. Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.
Forsythe HL; Jarvis JL; Turner JW; Elmore LW; Holt SE
J Biol Chem; 2001 May; 276(19):15571-4. PubMed ID: 11274138
[TBL] [Abstract][Full Text] [Related]
17. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
19. Definition of the minimal fragments of Sti1 required for dimerization, interaction with Hsp70 and Hsp90 and in vivo functions.
Flom G; Behal RH; Rosen L; Cole DG; Johnson JL
Biochem J; 2007 May; 404(1):159-67. PubMed ID: 17300223
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
